Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMBFE74)

Drug Name
Milnacipran Drug Info
Synonyms
Ixel; Midalcipran; Milnacipranum; Toledomin; Milnacipran [INN]; Milnacipranum [Latin]; F 2207; F-2207; Ixel (TN); Milnacipran(INN); Savella (TN); (+-)-cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; 1-phenyl-1-diethylaminocarbonyl-2-aminomethylcyclopropane HCl
Therapeutic ClassAntidepressants
Cross-matching ID
PubChem CID
65833
ChEBI ID
CHEMBL94468
CAS Number
CAS 96847-55-1
TTD Drug ID
D09VGC
VARIDT Drug ID
DR00947
ACDINA Drug ID
D00435

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ribosome 2.23 0.00e+0 113/158 (71.52%) RPS4Y1;RPL36;MRPL15;...
Proteasome 2.21 0.00e+0 44/46 (95.65%) PSMA6;PSMB8;PSMD4;...
Oxidative phosphorylation 2.08 0.00e+0 93/133 (69.92%) COX7B;NDUFB5;SDHD;...
Parkinson disease 2.02 0.00e+0 176/249 (70.68%) PSMA6;TXN;COX7B;...
Amyotrophic lateral sclerosis 1.99 0.00e+0 267/364 (73.35%) NEFH;GPX7;GPX2;...
Prion disease 1.89 7.70e-3 209/273 (76.56%) HSPA8;PSMA6;COX7B;...
Pyrimidine metabolism 1.87 7.42e-3 40/56 (71.43%) UCK2;CTPS1;NME1;...
Complement and coagulation cascades 1.84 1.08e-2 76/85 (89.41%) PLAT;CFI;C3;...
Diabetic cardiomyopathy 1.78 1.80e-2 162/203 (79.8%) AGT;PLN;COX7B;...
Huntington disease 1.78 1.62e-2 233/306 (76.14%) GPX7;GPX2;PSMA6;...
Cysteine and methionine metabolism 1.78 1.47e-2 43/50 (86%) LDHA;DNMT3A;CDO1;...
Pyruvate metabolism 1.73 1.88e-2 41/47 (87.23%) ADH5;LDHA;ADH1B;...
DNA replication 1.70 2.31e-2 34/36 (94.44%) POLE2;PCNA;RPA3;...
PPAR signaling pathway 1.68 2.76e-2 66/74 (89.19%) LPL;FABP1;PCK1;...
Pathways of neurodegeneration 1.66 3.23e-2 354/475 (74.53%) NEFH;GPX7;GPX2;...
Thermogenesis 1.63 3.72e-2 173/232 (74.57%) COX7B;NDUFB5;SDHD;...
Alzheimer disease 1.60 4.55e-2 279/369 (75.61%) LPL;PSMA6;COX7B;...
Proteoglycans in cancer -1.66 2.25e-2 172/205 (83.9%) GPC1;PRKCG;KDR;...
Axon guidance -1.66 2.32e-2 151/182 (82.97%) MAPK1;ROCK2;EPHB1;...
Human T-cell leukemia virus 1 infection -1.67 2.25e-2 197/219 (89.95%) TSPO;MAPK1;BCL2L1;...
Osteoclast differentiation -1.67 2.32e-2 117/127 (92.13%) IL1A;TGFBR2;PIK3R1;...
Morphine addiction -1.67 2.35e-2 80/91 (87.91%) GABRD;PDE1C;PDE7B;...
Bacterial invasion of epithelial cells -1.68 2.36e-2 59/77 (76.62%) ACTR2;CLTCL1;ELMO3;...
Insulin resistance -1.71 2.15e-2 96/108 (88.89%) PPARA;CREB1;PPP1CB;...
Viral myocarditis -1.72 1.86e-2 53/60 (88.33%) HLA-DMB;CASP3;HLA-DQB1;...
Pancreatic cancer -1.73 1.81e-2 75/76 (98.68%) MTOR;TGFBR2;PIK3R1;...
Growth hormone synthesis, secretion and action -1.73 1.90e-2 108/119 (90.76%) AKT3;CREB5;GNAS;...
Hematopoietic cell lineage -1.73 1.99e-2 90/99 (90.91%) IL7;CD8A;CD22;...
Tuberculosis -1.73 2.09e-2 159/180 (88.33%) MAPK1;BAX;CASP9;...
Mitophagy -1.74 2.21e-2 56/68 (82.35%) ATG9A;GABARAPL1;BCL2L1;...
ErbB signaling pathway -1.81 9.54e-3 79/85 (92.94%) GAB1;PTK2;MAP2K7;...
B cell receptor signaling pathway -1.81 1.01e-2 71/81 (87.65%) MAPK1;CD81;RAC3;...
Systemic lupus erythematosus -1.85 6.88e-3 45/135 (33.33%) ELANE;HLA-DMB;C2;...
Bladder cancer -1.85 7.37e-3 40/41 (97.56%) FGFR3;HBEGF;DAPK3;...
Renal cell carcinoma -1.88 6.80e-3 68/69 (98.55%) PIK3CA;EGLN2;PDGFB;...
Type II diabetes mellitus -1.95 1.23e-3 42/46 (91.3%) CACNA1A;MTOR;SLC2A4;...
Th1 and Th2 cell differentiation -1.96 0.00e+0 80/92 (86.96%) IL5;TYK2;JAK2;...
Primary immunodeficiency -1.97 0.00e+0 33/38 (86.84%) IL7R;RFX5;CIITA;...
Intestinal immune network for IgA production -2.03 0.00e+0 38/48 (79.17%) IL5;IL6;HLA-DPB1;...
Rheumatoid arthritis -2.04 0.00e+0 78/93 (83.87%) CXCL6;TCIRG1;CTSL;...
Lysosome -2.05 0.00e+0 115/128 (89.84%) M6PR;MANBA;HYAL1;...
Graft-versus-host disease -2.12 0.00e+0 32/42 (76.19%) IL6;HLA-DPB1;HLA-DMB;...
Asthma -2.12 0.00e+0 25/31 (80.65%) RNASE3;MS4A2;EPX;...
Autoimmune thyroid disease -2.14 0.00e+0 46/53 (86.79%) IL5;TSHR;HLA-DPB1;...
Type I diabetes mellitus -2.14 0.00e+0 38/43 (88.37%) GAD1;HLA-DPB1;HLA-DMB;...
Inflammatory bowel disease -2.14 0.00e+0 58/65 (89.23%) TLR5;TBX21;NOD2;...
Allograft rejection -2.34 0.00e+0 32/38 (84.21%) IL5;HLA-DPB1;HLA-DMB;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H